There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alnylam Pharma (ALNY – Research Report) and Immutep (IMMP – Research Report) with bullish sentiments. Alnylam Pharma (ALNY) Needham analyst Joseph Stringer maintained a Buy rating on Alnylam Pharma today and set a price target of $240.00. The company's shares closed last Wednesday at $202.21, close to its 52-week high of $212.00. According to TipRanks.com, Stringer is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -41.9% and a 10.5% success rate.
https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alnylam-pharma-alny-and-immutep-immp?utm_source=advfn.com&utm_medium=referral
Immutep (NASDAQ:IMMP)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more Immutep Charts.
Immutep (NASDAQ:IMMP)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more Immutep Charts.